Involvement of nuclear transcription factor-kappa B in low-dose doxorubicin-induced drug resistance of cervical carcinoma cells.

[1]  P. Yeh,et al.  Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. , 2002, Biochemical pharmacology.

[2]  K. Yeh,et al.  Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. , 2002, Biochemical pharmacology.

[3]  I. Chung,et al.  Down-regulation of DNA topoisomerase IIalpha in human colorectal carcinoma cells resistant to a protoberberine alkaloid, berberrubine. , 2002, Molecular pharmacology.

[4]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[5]  A. López-Rivas,et al.  The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels , 2001, Oncogene.

[6]  D. W. Kim,et al.  Increased and correlated nuclear factor-kappa B and Ku autoantigen activities are associated with development of multidrug resistance , 2001, Oncogene.

[7]  A. Fedier,et al.  Resistance to topoisomerase poisons due to loss of DNA mismatch repair , 2001, International journal of cancer.

[8]  M. J. van de Vijver,et al.  Determining MDR1/P‐glycoprotein expression in breast cancer , 2001, International journal of cancer.

[9]  Yan Song,et al.  Nuclear extracellular signal-regulated kinase 2 phosphorylates p53 at Thr55 in response to doxorubicin. , 2001, Biochemical and biophysical research communications.

[10]  H. Kalthoff,et al.  Inhibition of NF-κB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin , 2001, Oncogene.

[11]  A. Baldwin.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. , 2001, The Journal of clinical investigation.

[12]  R. Gaynor,et al.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. , 2001, The Journal of clinical investigation.

[13]  J. Molnár,et al.  Reversal of multidrug resistance of tumor cells. , 2000, Anticancer research.

[14]  G. Sledge,et al.  Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide , 2000, Oncogene.

[15]  G. Hunninghake,et al.  A constitutive active MEK --> ERK pathway negatively regulates NF-kappa B-dependent gene expression by modulating TATA-binding protein phosphorylation. , 2000, The Journal of biological chemistry.

[16]  T. Hofmann,et al.  The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. , 2000, European journal of biochemistry.

[17]  K. Vousden,et al.  Role of NF-κB in p53-mediated programmed cell death , 2000, Nature.

[18]  M. Mayo,et al.  The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. , 2000, Biochimica et biophysica acta.

[19]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[20]  T. Gilmore,et al.  Control of apoptosis by Rel/NF-κB transcription factors , 1999, Oncogene.

[21]  B. Rayet,et al.  Aberrant rel/nfkb genes and activity in human cancer , 1999, Oncogene.

[22]  J. Cusack,et al.  NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[23]  G. Dong,et al.  Expression of a Dominant-Negative Mutant Inhibitor-κBα of Nuclear Factor-κB in Human Head and Neck Squamous Cell Carcinoma Inhibits Survival, Proinflammatory Cytokine Expression, and Tumor Growth in Vivo , 1999 .

[24]  R. Hay,et al.  Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα , 1999, Oncogene.

[25]  B. Piret,et al.  The ATM protein is required for sustained activation of NF-κB following DNA damage , 1999, Oncogene.

[26]  J. Cusack,et al.  Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB , 1999, Nature Medicine.

[27]  M. Karin,et al.  An Essential Role for Nuclear Factor κB in Promoting Double Positive Thymocyte Apoptosis , 1999, The Journal of experimental medicine.

[28]  M. C. Hu,et al.  Protein Phosphatase X Interacts with c-Rel and Stimulates c-Rel/Nuclear Factor κB Activity* , 1998, The Journal of Biological Chemistry.

[29]  A. Baldwin,et al.  Activation of Nuclear Factor-κB-dependent Transcription by Tumor Necrosis Factor-α Is Mediated through Phosphorylation of RelA/p65 on Serine 529* , 1998, The Journal of Biological Chemistry.

[30]  Brendan D. Price,et al.  The DNA-Dependent Protein Kinase Participates in the Activation of NFκB Following DNA Damage , 1998 .

[31]  S. Ghosh,et al.  Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. , 1998, Molecular cell.

[32]  B. Dörken,et al.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. , 1997, The Journal of clinical investigation.

[33]  N. Baldini.  Multidrug resistance — a multiplex phenomenon , 1997, Nature Medicine.

[34]  S. McKenna,et al.  MULTIDRUG RESISTANCE IN LEUKAEMIA , 1997, Bailliere's clinical haematology.

[35]  Marty W. Mayo,et al.  TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.

[36]  Seamus J. Martin,et al.  Suppression of TNF-α-Induced Apoptosis by NF-κB , 1996, Science.

[37]  D. White,et al.  Rel/NF-kappaB/IkappaB proteins and cancer. , 1996, Oncogene.

[38]  C. Scheidereit,et al.  Activation of NF‐kappa B in vivo is regulated by multiple phosphorylations. , 1994, The EMBO journal.

[39]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[40]  I. Pastan,et al.  Biochemistry of multidrug resistance mediated by the multidrug transporter. , 1993, Annual review of biochemistry.